- 目次
-
CBC Group has invested in Taiwan Bio-Manufacturing Corporation (Headquarters: Taipei, Taiwan; CEO: David Chang; hereinafter referred to as “TBMC”) and we are pleased to announce that we have signed a Memorandum of Agreement (“Memorandum”) regarding collaboration in Japan.
The Memorandum covers the appointment of CBC as TBMC’s authorized agent for all products including Cell Therapy, Gene Therapy, Nucleic Acids, Vaccines, and Biologics in Japan. With the signing of Memorandum, CBC will bring TBMC’s innovative and high-capacity bioprocessing solutions to Japan market, and TBMC will enhance its customer service in Japan.
Taiwan Bio-Manufacturing Corporation (TBMC), conceived by the Ministry of Economic Affairs and jointly established by the Industrial Technology Research Institute (ITRI) and the Development Center for Biotechnology (DCB), officially commenced operations in May 2023. Dedicated to advancing biomanufacturing capabilities, TBMC partners with National Resilience, Inc. (Resilience), a technology-focused biomanufacturing company. Combining the expertise of National Resilience Inc. and Taiwan’s smart manufacturing capabilities, TBMC is dedicated to developing state-of-the-art solutions for the production of complex medicines, including (i)mRNA drug, (ii)viral vectors, (iii)cell therapy, and (iv)CHO-C protein pharmaceutical platforms.
TBMC operates from two primary manufacturing locations. Two Process Analytical Development Laboratories (PAD Labs; 1,820m2) are situated in the Taipei Bioinnovation Park and Hsinchu Biomedical Science Park. Both are slated for operational readiness and will have expanded operations in new facilities by June 2024 and December 2024, respectively. Meanwhile, the GMP plant (15,000m2) will be housed in the Hsinchu Biomedical Science Park and the facility will be commissioned and ready for GMP operation by the third quarter of 2025.
For more information, please visit the website.
https://tbmcbio.com/
